Sarah Spear
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Spear has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Iain A. McNeish
Department of Surgery and Cancer, Imperial College London, London, UK
46 shared publications - Fabio Grundland-Freile
Ovarian Cancer Action Research Centre, Department of Surgery & Cancer, Imperial College London; London, United Kingdom
42 shared publications - Hasan Mirza
Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
42 shared publications - Pavlina Spiliopoulou
School of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
42 shared publications Darren P. Ennis
24 shared publicationsNayana Iyer
24 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure legends from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Legends to supplementary figures
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure legends from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Legends to supplementary figures
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 Genes per cluster from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Genes upregulated in each mouse macrophage cluster
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 Genes per cluster from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Genes upregulated in each mouse macrophage cluster
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 Antibodies from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Table of antibodies used in flow cytometry and immunohistochemistry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Description of supplementary methods
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 HMOX1-hi gene expression from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Up- and down-regulated differentially expressed genes in HMOX1-hi human macrophages
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 HMOX1-hi gene expression from PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma
Up- and down-regulated differentially expressed genes in HMOX1-hi human macrophages
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Dual G9A/EZH2 inhibition inhibits tumor growth and prolongs survival in a mouse ovarian cancer model. A, Experimental design for mechanism experiments. Mice bearing intraperitoneal Trp53−/−ID8 cells were treated with either HKMTI-1–005 (20 mg/kg i.p. twice a day) or vehicle (1% Tween/3.4% DMSO in 0.9% NaCl i.p. twice a day) for 14 days starting on day 21, followed by omental and porta hepatic deposits harvest/weighting, measuring ascites and immunophenotyping by flow cytometry immediately after the end of treatment. Image created with BioRender.com. B, Experimental design for efficacy experiments. Mice were treated as per A, but treatment was followed by observation until mice reached humane survival endpoint. C, Kaplan–Meier survival curves for mice treated with vehicle (n = 24) or 20 mg/kg HKMTI-1–005 (n = 24) as per schedule on B. Median survival was 48 days for vehicle versus 54.5 days for HKMTI-1–005, P < 0.0001). Curves were compared using the Log-rank (Mantel–Cox) test, ****, P < 0.0001. Experiment was performed twice with n = 12 per cohort for each experiment. D, Whole tumor weight (including both porta hepatis and omental tumor deposits) and E ascites volume for mice treated with either vehicle (n = 20) or HKMTI-1–005 (n = 20) as per schedule in A; comparisons were made using unpaired t test for whole tumor burden and Mann–Whitney test for ascites volume (**, P < 0.01). Experiment was performed twice with n = 10 per cohort for each experiment.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Dual G9A/EZH2 inhibition inhibits tumor growth and prolongs survival in a mouse ovarian cancer model. A, Experimental design for mechanism experiments. Mice bearing intraperitoneal Trp53−/−ID8 cells were treated with either HKMTI-1–005 (20 mg/kg i.p. twice a day) or vehicle (1% Tween/3.4% DMSO in 0.9% NaCl i.p. twice a day) for 14 days starting on day 21, followed by omental and porta hepatic deposits harvest/weighting, measuring ascites and immunophenotyping by flow cytometry immediately after the end of treatment. Image created with BioRender.com. B, Experimental design for efficacy experiments. Mice were treated as per A, but treatment was followed by observation until mice reached humane survival endpoint. C, Kaplan–Meier survival curves for mice treated with vehicle (n = 24) or 20 mg/kg HKMTI-1–005 (n = 24) as per schedule on B. Median survival was 48 days for vehicle versus 54.5 days for HKMTI-1–005, P < 0.0001). Curves were compared using the Log-rank (Mantel–Cox) test, ****, P < 0.0001. Experiment was performed twice with n = 12 per cohort for each experiment. D, Whole tumor weight (including both porta hepatis and omental tumor deposits) and E ascites volume for mice treated with either vehicle (n = 20) or HKMTI-1–005 (n = 20) as per schedule in A; comparisons were made using unpaired t test for whole tumor burden and Mann–Whitney test for ascites volume (**, P < 0.01). Experiment was performed twice with n = 10 per cohort for each experiment.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
ATAC-seq and RNA-seq on murine omental tumor deposits. A, Number of ATAC-seq peaks for control (n = 6) and HKMTI-1–005 samples (n = 5), before applying filtration criteria. One HKMTI-1–005 sample did not yield enough sequencing reads and was removed from analysis. B, Distribution of ATAC-seq peaks across the genome. C, Overlap of genes with ATAC-seq peaks showing increased chromatin accessibility that were also differentially expressed (n = 1,106) by RNA-seq following HKMTI-1–005 treatment in vivo (HKMTI-1–005 n = 7, control n = 7). FC, fold change. Purple color: Log2FC ≥ 1, gray color: −1 < Log2FC ≤ 1, and blue color: Log2FC ≤ −1. D, Biological processes (BP) sub-ontology for 1,053 genes from C that overlapped with gene expression signatures from DAVID online Functional Annotation Tool. Gene count denotes the number of genes found to overlap with genes within the respective signature and the dot size represents the percentage of these genes within the signature. FE, fold enrichment. E and F, DEG following HKTMI-1–005 classified by BP and KEGG sub-ontologies, respectively. Gene count denotes the number of genes found to overlap with genes within the respective signature and the dot size represents the percentage of these genes within the signature. G, Volcano plot showing differentially expressed ERVs, following HKMTI treatment (n = 7) versus control (n = 7). Purple color: Log2FC ≥ 1, gray color: −1 < Log2FC ≤ 1 and green color: Log2FC ≤ −1. H, Volcano plot showing individual DEG following HKMTI treatment (n = 7) versus control (n = 7) by RNA sequencing with an FDR <0.05. Purple color: Log2FC ≥ 1, gray color: −1 < Log2FC ≤ 1 and green color: Log2FC ≤ −1. Cellular response to IFNβ (GO:0035458, FDR = 7.65e−15) and response to virus (GO:0009615, FDR = 4.32e−14).
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
ATAC-seq and RNA-seq on murine omental tumor deposits. A, Number of ATAC-seq peaks for control (n = 6) and HKMTI-1–005 samples (n = 5), before applying filtration criteria. One HKMTI-1–005 sample did not yield enough sequencing reads and was removed from analysis. B, Distribution of ATAC-seq peaks across the genome. C, Overlap of genes with ATAC-seq peaks showing increased chromatin accessibility that were also differentially expressed (n = 1,106) by RNA-seq following HKMTI-1–005 treatment in vivo (HKMTI-1–005 n = 7, control n = 7). FC, fold change. Purple color: Log2FC ≥ 1, gray color: −1 < Log2FC ≤ 1, and blue color: Log2FC ≤ −1. D, Biological processes (BP) sub-ontology for 1,053 genes from C that overlapped with gene expression signatures from DAVID online Functional Annotation Tool. Gene count denotes the number of genes found to overlap with genes within the respective signature and the dot size represents the percentage of these genes within the signature. FE, fold enrichment. E and F, DEG following HKTMI-1–005 classified by BP and KEGG sub-ontologies, respectively. Gene count denotes the number of genes found to overlap with genes within the respective signature and the dot size represents the percentage of these genes within the signature. G, Volcano plot showing differentially expressed ERVs, following HKMTI treatment (n = 7) versus control (n = 7). Purple color: Log2FC ≥ 1, gray color: −1 < Log2FC ≤ 1 and green color: Log2FC ≤ −1. H, Volcano plot showing individual DEG following HKMTI treatment (n = 7) versus control (n = 7) by RNA sequencing with an FDR <0.05. Purple color: Log2FC ≥ 1, gray color: −1 < Log2FC ≤ 1 and green color: Log2FC ≤ −1. Cellular response to IFNβ (GO:0035458, FDR = 7.65e−15) and response to virus (GO:0009615, FDR = 4.32e−14).
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Dual G9A/EZH2 inhibition changes peritoneal cavity immune cell composition and chemokine milieu in the spleen in a mouse ovarian cancer model. A, (Left) Density of NK cells (CD3− NK1.1+DX5+) in the peritoneal fluid with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment from mice bearing intraperitoneal Trp53−/− ID8 cells as per Fig. 4A. Statistical significance was tested by unpaired t test. (Right) Percentage IFNγ+ NK cells in peritoneal fluid from mice treated with vehicle (n = 6) versus HKMTI-1–005 (n = 7) treatment. Statistical significance was tested by unpaired t test. B, Representative flow cytometry plot from A. C, (Left) Density of regulatory T cells (CD4+FoxP3+) in peritoneal fluid from mice treated with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment. Statistical significance was tested by unpaired t test. (Right) Density of Ly6C+ cells in the peritoneal fluid from mice treated with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment. Statistical significance was tested by unpaired t test. D, Representative flow cytometry plot from D. E, CXCR3 MFI on CD3+ (n = 7 vehicle and n = 8 HKMTI-1–005), CD4+ (n = 7 vehicle and n = 8 HKMTI-1–005), CD8+ (n = 7 vehicle and n = 8 HKMTI-1–005), and NK cells (n = 7 vehicle and n = 8 HKMTI-1–005) in the peritoneal fluid. Unpaired t test was used to compare all mean values except NK-cell comparison where the Mann–Whitney test was used. F, Representative MFI histogram on one sample from E; FMO, fluorescence-minus-one. G and H. Percentage of IFNγ, perforin, and GZMB+ CD8+ cells (G) and NK cells (H) within their respective overall populations in spleen, following ex vivo stimulation with PMA and ionomycin and protein transport inhibitors brefeldin and monensin in mice treated with either vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment. Statistical significance was tested by unpaired t test (****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant). Error bars represent SEM.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Dual G9A/EZH2 inhibition changes peritoneal cavity immune cell composition and chemokine milieu in the spleen in a mouse ovarian cancer model. A, (Left) Density of NK cells (CD3− NK1.1+DX5+) in the peritoneal fluid with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment from mice bearing intraperitoneal Trp53−/− ID8 cells as per Fig. 4A. Statistical significance was tested by unpaired t test. (Right) Percentage IFNγ+ NK cells in peritoneal fluid from mice treated with vehicle (n = 6) versus HKMTI-1–005 (n = 7) treatment. Statistical significance was tested by unpaired t test. B, Representative flow cytometry plot from A. C, (Left) Density of regulatory T cells (CD4+FoxP3+) in peritoneal fluid from mice treated with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment. Statistical significance was tested by unpaired t test. (Right) Density of Ly6C+ cells in the peritoneal fluid from mice treated with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment. Statistical significance was tested by unpaired t test. D, Representative flow cytometry plot from D. E, CXCR3 MFI on CD3+ (n = 7 vehicle and n = 8 HKMTI-1–005), CD4+ (n = 7 vehicle and n = 8 HKMTI-1–005), CD8+ (n = 7 vehicle and n = 8 HKMTI-1–005), and NK cells (n = 7 vehicle and n = 8 HKMTI-1–005) in the peritoneal fluid. Unpaired t test was used to compare all mean values except NK-cell comparison where the Mann–Whitney test was used. F, Representative MFI histogram on one sample from E; FMO, fluorescence-minus-one. G and H. Percentage of IFNγ, perforin, and GZMB+ CD8+ cells (G) and NK cells (H) within their respective overall populations in spleen, following ex vivo stimulation with PMA and ionomycin and protein transport inhibitors brefeldin and monensin in mice treated with either vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment. Statistical significance was tested by unpaired t test (****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, nonsignificant). Error bars represent SEM.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Dual G9A/EZH2 inhibition changes intratumoral immune cell composition in a mouse ovarian cancer model. A, Quantitative result for NK cells (CD3− DX5+) cells in porta hepatis deposits with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment and in the omental deposits in mice treated with vehicle (n = 9) versus HKMTI-1–005 (n = 8) treatment from mice bearing intraperitoneal Trp53−/− ID8 cells were treated with either HKMTI-1–005 or vehicle as per Fig. 4A. Significance was tested using an unpaired t test. B, Percentage of effector CD8+ cells (CD44+CD62L−) within the total CD8+ population in porta hepatis deposits and omental deposits in mice treated with vehicle (n = 6 and 8, respectively) versus HKMTI-1–005 (n = 7 and 8, respectively) treatment. Significance was tested using an unpaired t test. C, Percentage of naïve CD8+ (CD44− CD62L+) within the total CD8+ population in porta hepatis deposits and omental deposits in mice treated with vehicle (n = 6 and 8, respectively) versus HKMTI-1–005 (n = 7 and 8, respectively) treatment. Significance was tested using an unpaired t test (porta hepatis) and Mann–Whitney test (omental deposit). D, Representative contour plot from one of the omental deposits for effector and naïve CD8+ cells, in mice treated with vehicle versus HKMTI-1–005 treatment. E, Percentage of granzyme-B (GZMB+) CD8+ cells, following stimulation, within the total CD8+ population in porta hepatis deposits and omental deposits from mice treated with vehicle (n = 9 and 8, respectively) versus HKMTI-1–005 (n = 9 and 8, respectively) treatment. Statistical significance was tested by unpaired t test. F, Representative contour plot showing (GZMB+) CD8+ cells from one of the omental deposits from E. G, Quantitative result for T regulatory CD4+ cells (FoxP3+ CD4+) cells in porta hepatis deposits and omental deposits with vehicle (n = 9 and 8, respectively) versus HKMTI-1–005 (n = 9 and 8, respectively) treatment. Unpaired t test (porta hepatis deposits) and Mann–Whitney test (omental deposits). H, CXCR3 MFI on CD3+ (n = 9 vehicle and n = 8 HKMTI-1–005), CD4+ (n = 6 vehicle and n = 6 HKMTI-1–005), CD8+ (n = 6 vehicle and n = 7 HKMTI-1–005), and NK cells (n = 7 vehicle and n = 8 HKMTI-1–005) in the porta hepatis deposits. Statistical significance was tested by unpaired t-test. I, CXCR3 MFI on CD3+ (n = 9 vehicle and n = 8 HKMTI-1–005), CD4+ (n = 9 vehicle and n = 8 HKMTI-1–005), CD8+ (n = 8 vehicle and n = 8 HKMTI-1–005), and NK cells (n = 9 vehicle and n = 8 HKMTI-1–005) in omental deposits. Unpaired t test. J, CD206 MFI on cDC1 dendritic cells (CD11b−MHCII+CD11c+) in porta hepatis deposits (n = 4 vehicle and n = 1 HKMTI-1–005, statistics not performed as n < 3) and omental deposits (n = 6 vehicle and n = 5 HKMTI-1–005). Statistical significance was tested by unpaired t test. K, Ly6C+ macrophages (CD11b+MHCII+F4/80+) in porta hepatis and omentum deposits with vehicle (both n = 7) versus HKMTI-1–005 (n = 7 and 8, respectively) treatment. Statistical significance was tested by the Mann–Whitney test. L, Representative flow cytometry plot with pseudocolour heatmap showing Ly6C+ macrophages from a representative omental deposit from K. cDC2+ cells were subsequently gated on a CD11c+ (****, P < 0.0001; ***, P < 0.001; **, P <0.01; *, P < 0.05; ns, nonsignificant). Error bars represent SEM.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma
Dual G9A/EZH2 inhibition changes intratumoral immune cell composition in a mouse ovarian cancer model. A, Quantitative result for NK cells (CD3− DX5+) cells in porta hepatis deposits with vehicle (n = 7) versus HKMTI-1–005 (n = 8) treatment and in the omental deposits in mice treated with vehicle (n = 9) versus HKMTI-1–005 (n = 8) treatment from mice bearing intraperitoneal Trp53−/− ID8 cells were treated with either HKMTI-1–005 or vehicle as per Fig. 4A. Significance was tested using an unpaired t test. B, Percentage of effector CD8+ cells (CD44+CD62L−) within the total CD8+ population in porta hepatis deposits and omental deposits in mice treated with vehicle (n = 6 and 8, respectively) versus HKMTI-1–005 (n = 7 and 8, respectively) treatment. Significance was tested using an unpaired t test. C, Percentage of naïve CD8+ (CD44− CD62L+) within the total CD8+ population in porta hepatis deposits and omental deposits in mice treated with vehicle (n = 6 and 8, respectively) versus HKMTI-1–005 (n = 7 and 8, respectively) treatment. Significance was tested using an unpaired t test (porta hepatis) and Mann–Whitney test (omental deposit). D, Representative contour plot from one of the omental deposits for effector and naïve CD8+ cells, in mice treated with vehicle versus HKMTI-1–005 treatment. E, Percentage of granzyme-B (GZMB+) CD8+ cells, following stimulation, within the total CD8+ population in porta hepatis deposits and omental deposits from mice treated with vehicle (n = 9 and 8, respectively) versus HKMTI-1–005 (n = 9 and 8, respectively) treatment. Statistical significance was tested by unpaired t test. F, Representative contour plot showing (GZMB+) CD8+ cells from one of the omental deposits from E. G, Quantitative result for T regulatory CD4+ cells (FoxP3+ CD4+) cells in porta hepatis deposits and omental deposits with vehicle (n = 9 and 8, respectively) versus HKMTI-1–005 (n = 9 and 8, respectively) treatment. Unpaired t test (porta hepatis deposits) and Mann–Whitney test (omental deposits). H, CXCR3 MFI on CD3+ (n = 9 vehicle and n = 8 HKMTI-1–005), CD4+ (n = 6 vehicle and n = 6 HKMTI-1–005), CD8+ (n = 6 vehicle and n = 7 HKMTI-1–005), and NK cells (n = 7 vehicle and n = 8 HKMTI-1–005) in the porta hepatis deposits. Statistical significance was tested by unpaired t-test. I, CXCR3 MFI on CD3+ (n = 9 vehicle and n = 8 HKMTI-1–005), CD4+ (n = 9 vehicle and n = 8 HKMTI-1–005), CD8+ (n = 8 vehicle and n = 8 HKMTI-1–005), and NK cells (n = 9 vehicle and n = 8 HKMTI-1–005) in omental deposits. Unpaired t test. J, CD206 MFI on cDC1 dendritic cells (CD11b−MHCII+CD11c+) in porta hepatis deposits (n = 4 vehicle and n = 1 HKMTI-1–005, statistics not performed as n < 3) and omental deposits (n = 6 vehicle and n = 5 HKMTI-1–005). Statistical significance was tested by unpaired t test. K, Ly6C+ macrophages (CD11b+MHCII+F4/80+) in porta hepatis and omentum deposits with vehicle (both n = 7) versus HKMTI-1–005 (n = 7 and 8, respectively) treatment. Statistical significance was tested by the Mann–Whitney test. L, Representative flow cytometry plot with pseudocolour heatmap showing Ly6C+ macrophages from a representative omental deposit from K. cDC2+ cells were subsequently gated on a CD11c+ (****, P < 0.0001; ***, P < 0.001; **, P <0.01; *, P < 0.05; ns, nonsignificant). Error bars represent SEM.